“…It should also be respected in therapeutics design that, as discussed above, the varied permutations of the condition of the host, as well as the adaptations of the colonizing microbes and the treatments being received, are likely to keep the infectious landscape ever-changing [8,20,43,133]. The P. aeruginosa variability and fluidity in the expression or lack of expression of virulence features and structures are expected to complicate the development of targeted agents [10,11,15,20,24,26,29,36,58,63,88,90,116,117,131,136]. The distinctions and differences in complex mucosal glycoconjugates are anticipated in CF respiratory tracts and are mechanistically important to bacterial binding and/or clearance [9,60,65,67,78,79,81,82].…”